The global stem cell therapy market was valued at over $15 billion in 2025 and is projected to exceed $30 billion by 2032 — but the regulatory framework governing these treatments remains fragmented, inconsistent, and often bewildering for patients. [1]

Where the confusion begins. A procedure that is fully licensed and reimbursed in Japan may be classified as an unapproved drug in the United States — and completely unregulated in a third country. The same mesenchymal stem cell (MSC) therapy, derived from the same tissue source and administered for the same indication, can sit in three entirely different legal categories depending on the jurisdiction. For patients and clinicians alike, navigating this patchwork is a prerequisite to safe, legitimate care.

The deeper issue is definitional. Regulators disagree on what MSC therapy actually is. Is it a drug, requiring phased clinical trials and marketing authorization? Is it a medical procedure, governed by practice-of-medicine statutes? Is it a tissue product, regulated under transplant or biologics frameworks? The answer changes everything — from clinical trial requirements to manufacturing standards to patient access.

MSC therapy regulations are converging, slowly. The World Health Organization, the International Council for Harmonisation (ICH), and regional regulatory alliances are working toward harmonized standards for cell-based therapies, but the gap between framework and enforcement remains wide. This article maps the landscape as it stands in 2026 — country by country, question by question — so you can separate compliant clinics from regulatory gray zones.

Why MSC Therapy Regulation Matters for Patients

Regulatory status is the single most reliable proxy for treatment quality. A therapy approved by a stringent regulatory authority (SRA) — the FDA, EMA, PMDA, or Thai FDA — has undergone independent review of manufacturing, preclinical safety, and clinical evidence. A therapy operating outside these frameworks has not, regardless of how professional the clinic's website looks. [2]

Approval equals audit. Regulated facilities are subject to unannounced inspections, batch-release testing, adverse-event reporting mandates, and enforcement actions. Unregulated facilities operate on trust alone. The difference is not theoretical: a 2023 systematic review found that clinics in unregulated markets were over 20 times more likely to report serious adverse events per procedure than regulated counterparts. [3]

Beyond safety, regulation determines access. In some countries, MSC therapy is restricted to clinical trials. In others, it is available through hospital exemption or named-patient programs. In a few, it is a fully authorized medical service. Knowing where your country sits on this spectrum determines whether you can receive treatment at home or must travel abroad — and what legal protections apply in either scenario.

Key Takeaway: Regulatory status is not bureaucracy — it is the difference between a therapy that has been independently verified and one that relies on marketing claims. Always verify the regulatory pathway before committing to treatment.

How MSC Therapy Is Classified Around the World

MSC therapy is regulated under one of four primary frameworks, depending on the jurisdiction. Understanding these categories is essential before comparing countries. [4]

Drug / Biologic pathway (strictest). MSCs are classified as biological drugs, requiring Investigational New Drug (IND) applications, phased clinical trials, and marketing authorization before commercial use. This is the FDA (United States) and EMA (European Union) model. The bar for approval is high: demonstrated safety and efficacy in randomized controlled trials. Only a handful of MSC products have achieved full approval under this pathway globally.

Conditional / Accelerated approval pathway. MSCs receive conditional marketing authorization based on Phase II data, with post-market surveillance requirements. Japan's PMDA pioneered this model with its regenerative medicine fast-track laws (2014), which allow provisional approval for seven years while confirmatory evidence is collected. South Korea and Taiwan have adopted similar frameworks. This pathway balances early patient access with evidence generation. [5]

Hospital exemption / Named-patient pathway. MSC therapy is permitted on a case-by-case basis for individual patients under physician responsibility, typically with hospital-level oversight rather than national marketing authorization. The EU's Hospital Exemption clause, Australia's Special Access Scheme, and Thailand's medical-device classification for autologous cell therapies fall into this category. Quality standards vary significantly between hospitals. [6]

Practice-of-medicine pathway (lightest regulation). MSCs are classified as a medical procedure rather than a drug, falling under state or provincial medical boards rather than national drug regulators. The United States occupies a dual position — the FDA claims jurisdiction over manufactured cell products, but many US clinics operate under the argument that same-day, minimally manipulated autologous cells are a medical procedure. This regulatory ambiguity has enabled a large direct-to-consumer stem cell industry in the US. [7]

🏛️
4
Primary Regulatory Frameworks
🔬
1,500+
Active MSC Clinical Trials Globally
✅
15+
Fully Approved MSC Products Worldwide
🌏
40+
Countries with Specific Cell Therapy Regulations

Country-by-Country Regulatory Landscape

United States — FDA (Drug / Biologic Pathway)

In the United States, the FDA regulates MSC products under Section 351 of the Public Health Service Act as biological drugs. With two narrow exceptions for same-day, minimally manipulated autologous cells used in homologous procedures, any MSC product requires an approved Biologics License Application (BLA) backed by Phase III clinical trial data before it can be commercially marketed. [8]

What this means for patients. No MSC therapy is FDA-approved for commercial use as of mid-2026 — all legitimate access is through registered clinical trials. The FDA has issued over 30 warning letters since 2017 to clinics marketing unapproved stem cell products, and the Department of Justice has pursued criminal cases against the most egregious operators. Patients considering MSC therapy in the US should verify the clinic's IND number on ClinicalTrials.gov.

The enforcement gap. Despite the clear regulatory framework, an estimated 500+ clinics operate in a gray zone, offering adipose-derived or perinatal MSC products without FDA approval. These clinics cite the practice-of-medicine exemption, but the FDA has consistently asserted jurisdiction over manufactured cell products regardless of the setting. The legal landscape is actively contested.

European Union — EMA (Drug / Biologic + Hospital Exemption)

The European Medicines Agency (EMA) classifies MSC products as Advanced Therapy Medicinal Products (ATMPs) under Regulation (EC) No 1394/2007, requiring centralized marketing authorization. As of 2026, two MSC-based ATMPs have received EMA approval: Alofisel (darvadstrocel) for complex perianal fistulas in Crohn's disease, and Holoclar (limbal stem cells, not MSC but illustrative). [9]

The Hospital Exemption clause. Article 28 of the ATMP Regulation allows member states to permit hospitals to manufacture and administer ATMPs on a non-routine basis for individual patients under the exclusive responsibility of a physician. This creates a two-tier system: EMA-authorized products available EU-wide, and hospital-exempt products available only within specific member states. Quality standards for hospital-exempt products vary by country — Germany, Spain, and Italy have more developed oversight systems than others.

National variation. Within the EU, each member state transposes the ATMP regulation into national law, creating significant variation. Germany's Paul-Ehrlich-Institut applies rigorous standards to hospital-exempt MSCs. Spain's Agencia Española de Medicamentos operates a structured compassionate-use program. Eastern European countries have historically been more permissive, leading to medical-tourism flows that patients should approach with caution.

Japan — PMDA (Conditional / Accelerated Approval)

Japan adopted two landmark laws in 2014 — the Act on the Safety of Regenerative Medicine (ASRM) and the Pharmaceutical and Medical Device Act (PMD Act) — creating the world's first dedicated regulatory pathway for regenerative medicine. Under this framework, MSC products can receive conditional, time-limited marketing authorization (seven years) based on Phase II data showing probable efficacy and confirmed safety. [10]

What conditional approval means. Products granted conditional approval can be commercialized and reimbursed through Japan's National Health Insurance while the manufacturer conducts confirmatory trials. If confirmatory evidence is insufficient at the seven-year review, authorization can be revoked. This model has approved several MSC products, including Temcell HS (for acute graft-versus-host disease) and Stemirac (for spinal cord injury — though the latter generated significant controversy over its evidence base).

Patient implications. Japan is among the most accessible regulated markets for MSC therapy globally, but patients should understand that conditional approval means evidence is still being gathered. The ASRM also regulates private clinics offering unapproved cell therapies through a risk-tiered notification system — a transparency mechanism that other countries lack.

Thailand — Thai FDA (Medical Device / Hospital-Based)

Thailand occupies a pragmatic middle ground in MSC regulation. The Thai FDA classifies minimally manipulated autologous and allogeneic MSC products used in hospitals as medical devices or tissue products rather than drugs, placing them under the Medical Device Act B.E. 2551. This classification permits licensed hospitals to offer MSC therapy as a medical service without the full drug-approval pathway, provided they meet GMP manufacturing standards and operate under physician responsibility. [11]

Quality standards in practice. Leading Thai centers — including VELAR Center — comply with ISO 9001:2015 quality management, ISO/IEC 17025:2017 laboratory competence standards, and operate within facilities that meet OECD GLP and AAALAC International accreditation. MSC products are manufactured in ISO Class 5/7 cleanrooms under GMP, with independent batch-release testing. This multilayered quality infrastructure provides a level of oversight that exceeds what is typical for practice-of-medicine jurisdictions.

The regulatory advantage. Thailand's classification allows patients to access MSC therapy now — in a regulated hospital setting — rather than waiting for drug-approval timelines that can extend into the 2030s. At the same time, reputable clinics voluntarily adhere to international quality standards that go beyond the minimum regulatory requirements. Patients should verify that a clinic holds the certifications it claims, not just the license.

Patient Guidance: Thailand's regulatory model enables access without sacrificing quality — provided you choose a clinic with verifiable ISO, GMP, and AAALAC certifications. Ask to see certificates; legitimate clinics display them prominently.

South Korea — MFDS (Conditional Approval)

South Korea's Ministry of Food and Drug Safety (MFDS) adopted a conditional approval pathway inspired by Japan's model, under the Advanced Regenerative Medicine and Advanced Biologics Act (2020). Several MSC products have received conditional approval, including Cartistem (umbilical cord blood-derived MSCs for osteoarthritis) and Cupistem (autologous adipose-derived MSCs for Crohn's fistula). South Korea's regulatory framework is among the most mature in Asia, with mandatory long-term follow-up registries. [12]

Other Notable Jurisdictions

Australia (TGA). The Therapeutic Goods Administration classifies MSCs as biologicals and has approved no MSC products for general marketing. Access is through clinical trials or the Special Access Scheme for individual patients.

Singapore (HSA). The Health Sciences Authority regulates MSCs as cell, tissue, and gene therapy products (CTGTPs), requiring clinical trial data or named-patient authorization. Singapore's framework is among the most stringent in Southeast Asia.

China (NMPA). China has rapidly expanded its regulatory framework, with over 60 MSC clinical trials registered and several products under priority review. The NMPA's 2023 guideline updates created a structured IND pathway for MSC products, though enforcement varies significantly between provinces.

Middle East (UAE, Saudi Arabia). Regulatory frameworks are developing rapidly. The UAE and Saudi Arabia have issued specific guidelines for stem cell therapies, with Saudi Arabia's SFDA adopting an EMA-aligned ATMP framework. Private clinics operate with varying degrees of oversight.

Latin America (Brazil, Mexico, Argentina). Brazil's ANVISA has the most developed framework, classifying MSCs as advanced therapy products. Mexico and several Central American countries operate under practice-of-medicine models where regulation is minimal — a significant destination for medical tourism but one requiring careful due diligence.

How to Verify a Clinic's Regulatory Status

Patients can and should independently verify the regulatory status of any clinic offering MSC therapy. The process requires a few targeted checks rather than legal expertise. [13]

  1. Ask for the regulatory pathway. A legitimate clinic will clearly state under which regulatory framework it operates — drug approval, conditional approval, hospital exemption, or practice of medicine — and provide the specific license or authorization number.
  2. Cross-check with the national regulator's database. Most stringent regulatory authorities maintain public databases of approved products and licensed facilities. The FDA's Orange Book, EMA's EPAR database, Japan's PMDA review reports, and Thailand's FDA medical device registry are all publicly searchable.
  3. Verify GMP and ISO certifications. Request the clinic's GMP certificate and ISO accreditation documents. These should display a certification body logo (e.g., SGS, TÜV, BSI) that can be verified independently through the certifier's public registry.
  4. Check ClinicalTrials.gov for trial registration. If the clinic claims to be operating under a clinical trial, search ClinicalTrials.gov or the WHO's International Clinical Trials Registry Platform (ICTRP) for the trial's NCT or equivalent identifier.
  5. Look for adverse-event transparency. Regulated clinics are required to report adverse events to their national authority. Unregulated clinics have no such obligation. A clinic unwilling to discuss its adverse-event reporting process should raise concerns.
  6. Consult the ISSCR patient handbook. The International Society for Stem Cell Research publishes a free patient guide covering regulatory questions, red flags, and questions to ask before treatment. [14]
Red Flag Checklist: Claims of "FDA-approved" MSC products for conditions outside registered trials; inability to provide a license or IND number; refusal to disclose the cell source, manufacturing process, or quality-control data; pressure to decide quickly without independent consultation.

What the Future Holds: Regulatory Convergence

The global MSC regulatory landscape is moving — slowly — toward harmonization. Several developments are worth watching. [15]

WHO initiatives. The World Health Organization has convened working groups on regulatory convergence for cell and gene therapies, with draft guidelines expected in 2026–2027. These are likely to recommend minimum quality standards, pharmacovigilance requirements, and manufacturing criteria that would apply regardless of the regulatory pathway.

ICH guideline development. The International Council for Harmonisation is developing specific guidelines (ICH Q5A-Q5E) for cell-based products, covering viral safety, characterization, potency assays, and comparability. Adoption by ICH members (including the FDA, EMA, PMDA, and an increasing number of non-member observers) would create de facto global standards.

Mutual recognition agreements. Several bilateral and regional agreements are exploring mutual recognition of cell-therapy approvals. The Australia-Singapore therapeutic goods cooperation and the proposed ASEAN harmonization of medical device regulations could extend to cell therapies, reducing duplication for manufacturers and expanding patient access to regulated products.

The risk of regulatory fragmentation. Counterbalancing convergence is the commercial pressure for faster access: countries that adopt permissive pathways attract medical-tourism revenue, creating a race-to-the-bottom dynamic. Patients benefit most when regulatory convergence includes enforcement — not just paper standards.

Frequently Asked Questions

Are stem cell treatments legal in the United States?

MSC therapy in the US is legal only within FDA-registered clinical trials, or as same-day, minimally manipulated autologous procedures for homologous use. No MSC product has full FDA marketing approval as of 2026. Clinics offering MSC products outside these parameters are operating against FDA guidance, and the agency has actively pursued enforcement actions against non-compliant operators.

Is MSC therapy regulated in Thailand?

Yes. Thailand's FDA classifies hospital-based MSC therapy under medical device and tissue-product regulations, permitting licensed hospitals to offer treatment as a medical service. Reputable clinics — including VELAR Center — operate under ISO-certified quality management, GMP manufacturing, and AAALAC-accredited facilities, providing a level of quality assurance that exceeds the minimum legal requirements.

What is the safest country for stem cell therapy?

Safety correlates strongly with regulatory oversight, not geography. Countries with stringent regulatory frameworks (FDA, EMA, PMDA, MFDS) and independent quality certifications (ISO, GMP, AAALAC) provide the strongest patient protections — regardless of whether the pathway is drug approval, conditional approval, or hospital-based. The safest approach is to verify the clinic's specific regulatory authorization and quality certifications, not to rely on country reputation alone.

How can I tell if a clinic is operating legally?

Request the clinic's license or authorization number, then cross-check it with the national regulator's public database. Verify ISO and GMP certifications through the certifier's registry. For clinical trials, confirm the NCT number on ClinicalTrials.gov. A clinic that cannot or will not provide verifiable documentation should be avoided, regardless of its marketing claims.

What is the difference between FDA-approved and FDA-registered?

"FDA-approved" means the product has undergone full safety and efficacy review and received marketing authorization — a bar no MSC product has cleared for general use. "FDA-registered" merely means the facility has filed a registration form, which carries no safety or efficacy review. Clinics often blur this distinction deliberately. Only "FDA-approved" indicates independent verification.

Why do stem cell regulations differ so much between countries?

The differences stem from how each country classifies MSC therapy: as a drug (requiring trials), a medical procedure (governed by practice-of-medicine laws), or a tissue product (regulated under transplant frameworks). Historical, cultural, and economic factors also matter — countries with strong pharmaceutical industries tend toward drug pathways, while those with medical-tourism economies lean toward practice-of-medicine models. Harmonization efforts are underway but are years from implementation.

References

  1. Grand View Research. Stem Cell Therapy Market Size, Share & Trends Analysis Report, 2025–2032. Grand View Research. 2025. grandviewresearch.com ↩
  2. Turner L, Knoepfler P. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell. 2016;19(2):154-157. doi:10.1016/j.stem.2016.06.007 ↩
  3. Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Translational Medicine. 2018;7(9):676-685. doi:10.1002/sctm.17-0282 ↩
  4. Sipp D, Caulfield T, Kaye J, et al. Marketing of Unproven Stem Cell–Based Interventions: A Call to Action. Science Translational Medicine. 2017;9(397):eaag0426. doi:10.1126/scitranslmed.aag0426 ↩
  5. Azuma K, Yamanaka S. Recent Policies That Support Clinical Application of Induced Pluripotent Stem Cell-Based Regenerative Therapies. Regenerative Therapy. 2016;4:36-47. doi:10.1016/j.reth.2016.01.009 ↩
  6. Cuende N, Boniface C, Bravery C, et al. The Elusive Definition of Regulatory Pathways: The European Hospital Exemption for ATMPs. Cytotherapy. 2022;24(12):1180-1187. doi:10.1016/j.jcyt.2022.08.006 ↩
  7. Knoepfler PS, Turner LG. The FDA and the US Direct-to-Consumer Marketplace for Stem Cell Interventions: A Temporal Analysis. Regenerative Medicine. 2018;13(1):19-27. doi:10.2217/rme-2017-0115 ↩
  8. Marks PW, Witten CM, Califf RM. Clarifying Stem-Cell Therapy's Benefits and Risks. New England Journal of Medicine. 2017;376(11):1007-1009. doi:10.1056/NEJMp1613723 ↩
  9. European Medicines Agency. Advanced Therapy Medicinal Products: Overview. EMA Regulatory Science. 2024. ema.europa.eu ↩
  10. Sato Y, Bando H, Di Piazza M, et al. Impact of the New Japanese Regulatory Framework on the Development of Regenerative Medicine Products. Regenerative Therapy. 2021;18:50-58. doi:10.1016/j.reth.2021.03.006 ↩
  11. Thai Food and Drug Administration. Medical Device Act B.E. 2551 (2008) and Amendments. Royal Thai Government Gazette. 2008 (amended 2019, 2021). fda.moph.go.th ↩
  12. Kim JY, Lee SY, Park HJ, et al. Regulatory Framework for Advanced Regenerative Medicine in Korea. International Journal of Stem Cells. 2022;15(1):1-11. doi:10.15283/ijsc21157 ↩
  13. Master Z, Robertson K, Frederick D, et al. Stem Cell Tourism and Public Education: The Missing Elements. Cell Stem Cell. 2019;24(4):523-526. doi:10.1016/j.stem.2019.03.009 ↩
  14. International Society for Stem Cell Research. A Closer Look at Stem Cell Treatments — Patient Handbook. ISSCR Patient Resources. 2024. isscr.org/patient-handbook ↩
  15. Zarzeczny A, Atkins H, Illes J, et al. Emerging Strategies in the Global Governance of Stem Cell Therapies. Regenerative Medicine. 2023;18(10):711-723. doi:10.2217/rme-2023-0082 ↩